{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:54:46Z","timestamp":1792364086426,"version":"4.4.0"},"reference-count":33,"publisher":"Wiley","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Reports in Rheumatology"],"published-print":{"date-parts":[[2023,12,12]]},"abstract":"<jats:p>Small cell neuroendocrine carcinoma is rare among urinary bladder cancer types, and to date, there are no case reports of concurrent antitranscriptional intermediary factor 1-\u03b3antibody-positive dermatomyositis. We describe the case of a 69-year-old Japanese man who presented with elevated creatine kinase levels and haematuria on medical examination. Approximately one month later, he developed dysphagia. Laryngoscopy confirmed laryngeal dysfunction. He also presented with muscle weakness and a skin rash. Magnetic resonance imaging of the upper extremities suggested bilateral brachial muscle myositis. He was diagnosed as having dermatomyositis and was later found to be positive for antitranscriptional intermediary factor 1-\u03b3 antibody. Computed tomography revealed an intravesical space-occupying lesion and right iliac lymphadenopathy, suggesting urinary bladder cancer. The patient was admitted to our hospital for treatment. Urinary bladder biopsy confirmed small cell neuroendocrine carcinoma because tumour cells were positive for synaptophysin, CD56, and chromogranin A. Thus, the patient was diagnosed as having an antitranscriptional intermediary factor 1-\u03b3antibody-positive dermatomyositis concomitant with urinary bladder small cell neuroendocrine carcinoma. The patient was treated with glucocorticoid and intravenous immune globulin therapy for dermatomyositis. Radiotherapy was selected for the carcinoma. Although muscle weakness and skin symptoms improved with treatment, dysphagia persisted. Furthermore, expression of the transcriptional intermediary factor 1-\u03b3 protein in tumour cells was also confirmed by immunohistochemistry, but the significance is unknown. It should be noted that antitranscriptional intermediary factor 1-\u03b3antibody-positive dermatomyositis can occur concomitantly with such a rare malignancy.<\/jats:p>","DOI":"10.1155\/2023\/8837463","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T17:35:09Z","timestamp":1702402509000},"page":"1-5","source":"Crossref","is-referenced-by-count":2,"title":["A Case Report of Anti-TIF1-\u03b3Antibody-Positive Dermatomyositis Concomitant with Small Cell Neuroendocrine Carcinoma of the Urinary Bladder"],"prefix":"10.1155","volume":"2023","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8019-383X","authenticated-orcid":true,"given":"Hiroyuki","family":"Hounoki","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Onose","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Asano","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Shinoda","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Tobe","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Noguchi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Hirabayashi","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Pathology, University of Toyama, Toyama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"A. Bohan","year":"1975","journal-title":"New England Journal of Medicine"},{"key":"2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/joim.12451","article-title":"Myositis-specific autoantibodies: an important tool to support diagnosis of myositis","volume":"280","author":"Z. Betteridge","year":"2016","journal-title":"Journal of Internal Medicine"},{"key":"3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"M. Satoh","year":"2017","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/OARRR.S231195","article-title":"Myositis specific autoantibodies: a clinical perspective","volume":"12","author":"F. M. Alenzi","year":"2020","journal-title":"Open Access Rheumatol"},{"key":"5","article-title":"The role of myositis-specific autoantibodies in the dermatomyositis spectrum","volume":"14","author":"H. Marasandra Ramesh","year":"2022","journal-title":"Cureus"},{"key":"6","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029477","article-title":"Advanced gallbladder cancer accompanied with cancer-associated dermatomyositis: a case report and literature review","volume":"101","author":"H. Kuroda","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2340\/00015555-3091","article-title":"Use of anti-transcriptional intermediary factor-1 gamma autoantibody in identifying adult dermatomyositis patients with cancer: a systematic review and meta-analysis","volume":"99","author":"M. Best","year":"2019","journal-title":"Acta Dermato-Venereologica"},{"key":"8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13256-021-02664-1","article-title":"Anti-transcription intermediary factor 1 gamma (TIF1\u03b3) antibody-positive dermatomyositis associated with ascending colon cancer: a case report and review of the literature","volume":"15","author":"R. Ono","year":"2012","journal-title":"Journal of Medical Case Reports"},{"key":"9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11071925","article-title":"Clinical characteristics of anti-TIF-1\u03b3antibody-positive dermatomyositis associated with malignancy","volume":"11","author":"Y. Harada","year":"2022","journal-title":"Journal of Clinical Medicine"},{"key":"10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12016-022-08922-4","article-title":"Autoantibody markers of increased risk of malignancy in patients with dermatomyositis","volume":"63","author":"M. Marz\u0119cka","year":"2022","journal-title":"Clinical Reviews in Allergy and Immunology"},{"key":"11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2478\/rjim-2018-0015","article-title":"Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia","volume":"56","author":"K. Sellami","year":"2018","journal-title":"Romanian Journal of Internal Medicine"},{"key":"12","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021733","article-title":"Malignancy in dermatomyositis: a retrospective paired case-control study of 202 patients from Central China","volume":"99","author":"L. Chang","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"13","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000021899","article-title":"Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies","volume":"99","author":"C. Shao","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"14","first-page":"619","article-title":"Paraneoplastic dermatomyositis associated with bladder cancer","volume":"15","author":"J. M. Sabio","year":"2006","journal-title":"Lupus"},{"key":"15","first-page":"997","article-title":"Dermatomyositis and small cell carcinoma of the bladder","volume":"55","author":"L. Sagi","year":"2009","journal-title":"Canadian Family Physician"},{"key":"16","first-page":"815","article-title":"A rare paraneoplastic dermatomyositis in bladder cancer with fatal outcome","volume":"10","author":"R. Xu","year":"2013","journal-title":"Urology Journal"},{"key":"17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.4103\/0974-7796.134299","article-title":"Recurrent dermatomyositis manifesting as a sign of recurrent transitional cell carcinoma of urinary bladder: long-term survival","volume":"6","author":"J. Fitzpatrick","year":"2014","journal-title":"Urology Annals"},{"key":"18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/art.33403","article-title":"Myositis-specific anti-155\/140 autoantibodies target transcription intermediary factor 1 family proteins","volume":"64","author":"M. Fujimoto","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"19","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"M. Fujimoto","year":"2016","journal-title":"Current Opinion in Rheumatology"},{"key":"20","article-title":"New gene evolution in the bonus-TIF1-\u03b3\/TRIM33 family impacted the architecture of the vertebrate dorsal-ventral patterning network","volume":"2309","author":"R. G. Wisotzkey","year":"2014","journal-title":"Molecular Biology and Evolution"},{"key":"21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3389\/fonc.2019.00979","article-title":"The roles of TIF1\u03b3 in cancer","volume":"9","author":"C. Yu","year":"2019","journal-title":"Frontiers Oncology"},{"key":"22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/MD.0b013e31829d08f9","article-title":"The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies","volume":"92","author":"L. G. Rider","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"S. L. Tansley","year":"2017","journal-title":"Journal of Autoimmunity"},{"key":"24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/art.33379","article-title":"Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis","volume":"64","author":"E. Trallero-Aragu\u00e1s","year":"2012","journal-title":"Arthritis and Rheumatism"},{"key":"25","article-title":"Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis","volume":"9","author":"X. Lu","year":"2014","journal-title":"PLoS One"},{"key":"26","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"A. Oldroyd","year":"2019","journal-title":"Rheumatology"},{"key":"27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jjco\/hyw034","article-title":"Urologic cancer in China","volume":"46","author":"C. Pang","year":"2016","journal-title":"Japanese Journal of Clinical Oncology"},{"key":"28","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-230185","article-title":"Primary small cell carcinoma of the urinary bladder","volume":"12","author":"S. Qayoom","year":"2019","journal-title":"BMJ Case Reports"},{"key":"29","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ejca.2011.08.012","article-title":"Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments","volume":"48","author":"C. M. Korse","year":"2012","journal-title":"European Journal of Cancer"},{"key":"30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"D. F. Fiorentino","year":"2015","journal-title":"Journal of the American Academy of Dermatology"},{"key":"31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154746","article-title":"Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies","volume":"11","author":"N. Mugii","year":"2016","journal-title":"PLoS One"},{"key":"32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/rheumatology\/kez572","article-title":"Anti-TIF1-\u03b3 autoantibodies: warning lights of a tumour autoantigen","volume":"59","author":"J. De Vooght","year":"2020","journal-title":"Rheumatology"},{"key":"33","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1111\/1346-8138.15526","article-title":"Clinical features of anti-transcription intermediary factor 1\u03b3 (TIF1\u03b3)-positive dermatomyositis with internal malignancy and investigation of the involvement of TIF1\u03b3 expression in tumors in the pathogenesis of cancer-associated dermatomyositis","volume":"47","author":"S. I. Motegi","year":"2020","journal-title":"The Journal of Dermatology"}],"container-title":["Case Reports in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/crirh\/2023\/8837463.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crirh\/2023\/8837463.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/crirh\/2023\/8837463.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T17:35:28Z","timestamp":1702402528000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/crirh\/2023\/8837463\/"}},"subtitle":[],"editor":[{"given":"Mario","family":"Salazar-Paramo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":33,"alternative-id":["8837463","8837463"],"URL":"https:\/\/doi.org\/10.1155\/2023\/8837463","relation":{},"ISSN":["2090-6897","2090-6889"],"issn-type":[{"value":"2090-6897","type":"electronic"},{"value":"2090-6889","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,12]]}}}